Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin for Diabetes Remission in Bariatric Surgery
NCT05207774Unknown
- Sponsor
- Soroka University Medical Center
- Start
- Jan 2020
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Randomised, double-blind trial of oxytocin nasal spray in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Soroka University Medical Center. Primary endpoints: Number of participants with diabetes remission at 1 year, Number of participants who improved their glycemic control at 8 weeks and 2 more. Status: unknown.
02
Drugs
oxytocin nasal spray
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05207774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207774.